Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis

  1. Teja Turk
  2. Nadine Bachmann
  3. Claus Kadelka
  4. Jürg Böni
  5. Sabine Yerly
  6. Vincent Aubert
  7. Thomas Klimkait
  8. Manuel Battegay
  9. Enos Bernasconi
  10. Alexandra Calmy
  11. Matthias Cavassini
  12. Hansjakob Furrer
  13. Matthias Hoffmann
  14. Huldrych F Günthard
  15. Roger D Kouyos  Is a corresponding author
  1. University Hospital Zurich, Switzerland
  2. University of Hospital Zurich, Switzerland
  3. University of Zurich, Switzerland
  4. Geneva University Hospitals, Switzerland
  5. University Hospital Lausanne, Switzerland
  6. University of Basel, Switzerland
  7. University Hospital Basel, Switzerland
  8. Regional Hospital of Lugano, Switzerland
  9. Geneva University Hospital, Switzerland
  10. Lausanne University Hospital, Switzerland
  11. University of Bern, Switzerland
  12. Cantonal Hospital St. Gallen, Switzerland
  13. University Hospital Zürich, Switzerland

Abstract

Assessing the danger of transition of HIV transmission from a concentrated to a generalized epidemic is of major importance for public health. In this study, we develop a phylogeny-based statistical approach to address this question. As a case study, we use this to investigate the trends and determinants of HIV transmission among Swiss heterosexuals. We extract the corresponding transmission clusters from a phylogenetic tree. To capture the incomplete sampling, the delayed introduction of imported infections to Switzerland, and potential factors associated with basic reproductive number R0, we extend the branching process model to infer transmission parameters. Overall, the R0 is estimated to be 0.44 (95%-confidence interval 0.42-0.46) and it is decreasing by 11% per 10 years (4%-17%). Our findings indicate rather diminishing HIV transmission among Swiss heterosexuals far below the epidemic threshold. Generally, our approach allows to assess the danger of self-sustained epidemics from any viral sequence data.

Article and author information

Author details

  1. Teja Turk

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3065-8578
  2. Nadine Bachmann

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7303-9542
  3. Claus Kadelka

    Division of Infectious Diseases and Hospital Epidemiology, University of Hospital Zurich, Zurich, Switzerland
    Competing interests
    No competing interests declared.
  4. Jürg Böni

    Institute of Medical Virology, University of Zurich, Zurich, Switzerland
    Competing interests
    No competing interests declared.
  5. Sabine Yerly

    Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
    Competing interests
    No competing interests declared.
  6. Vincent Aubert

    Divisions of Immunology and Allergy, University Hospital Lausanne, Lausanne, Switzerland
    Competing interests
    No competing interests declared.
  7. Thomas Klimkait

    Department of Biomedicine, University of Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
  8. Manuel Battegay

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
  9. Enos Bernasconi

    Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland
    Competing interests
    Enos Bernasconi, E.B. has been a consultant for BMS, Gilead, ViiV Healthcare, Pfizer, MSD, and Janssen; has received unrestricted research grants from Gilead, Abbott, Roche, and MSD; and has received travel grants from BMS, Boehringer Ingelheim, Gilead, MSD, and Janssen..
  10. Alexandra Calmy

    Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    Competing interests
    No competing interests declared.
  11. Matthias Cavassini

    Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland
    Competing interests
    No competing interests declared.
  12. Hansjakob Furrer

    Department of Infectious Diseases, University of Bern, Bern, Switzerland
    Competing interests
    Hansjakob Furrer, The institution of H.F. has received unrestricted grant support from ViiV, Gilead, Abbott, Janssen, Roche, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), and Boehringer Ingelheim..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1375-3146
  13. Matthias Hoffmann

    Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
    Competing interests
    No competing interests declared.
  14. Huldrych F Günthard

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Zürich, Switzerland
    Competing interests
    Huldrych F Günthard, H.F.G. has been an adviser and/or consultant for GlaxoSmithKline, Abbott, Gilead, Novartis, Boehringer Ingelheim, Roche, Tibotec, Pfizer, and BMS and has received unrestricted research and educational grants from Roche, Abbott, BMS, Gilead, Astra-Zeneca, GlaxoSmithKline, and MSD (all money to the institution)..
  15. Roger D Kouyos

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    For correspondence
    roger.kouyos@usz.ch
    Competing interests
    Roger D Kouyos, RDK has received speaker honoraria and travel grants from Gilead Sciences. None if these are in relation with the submitted manuscript..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9220-8348

Funding

Swiss National Science Foundation (33CS30-148522 and 159868)

  • Huldrych F Günthard

Swiss National Science Foundation (PZ00P3-142411)

  • Roger D Kouyos

Yvonne-Jacob Foundation

  • Huldrych F Günthard

University of Zurich's Clinical Research Priority Program's ZPHI

  • Huldrych F Günthard

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The SHCS was approved by the ethics committees of the participating institutions (Kantonale Ethikkommission Bern, Ethikkommission des Kantons St. Gallen, Comite Departemental d'Ethique des Specialites Medicales et de Medicine Communataire et de Premier Recours, Kantonale Ethikkommission Zürich, Repubblica e Cantone Ticino-Comitato Ethico Cantonale, Commission Cantonale d'Étique de la Recherche sur l'Être Humain, Ethikkommission beiderBasel; all approvals are available on http://www.shcs.ch/206-ethic-committee-approval-and-informed-consent), and written informed consent was obtained from all participants.

Copyright

© 2017, Turk et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,462
    views
  • 231
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Teja Turk
  2. Nadine Bachmann
  3. Claus Kadelka
  4. Jürg Böni
  5. Sabine Yerly
  6. Vincent Aubert
  7. Thomas Klimkait
  8. Manuel Battegay
  9. Enos Bernasconi
  10. Alexandra Calmy
  11. Matthias Cavassini
  12. Hansjakob Furrer
  13. Matthias Hoffmann
  14. Huldrych F Günthard
  15. Roger D Kouyos
(2017)
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis
eLife 6:e28721.
https://doi.org/10.7554/eLife.28721

Share this article

https://doi.org/10.7554/eLife.28721

Further reading

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Bo Zheng, Bronner P Gonçalves ... Caoyi Xue
    Research Article

    Background:

    In many settings, a large fraction of the population has both been vaccinated against and infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, quantifying the protection provided by post-infection vaccination has become critical for policy. We aimed to estimate the protective effect against SARS-CoV-2 reinfection of an additional vaccine dose after an initial Omicron variant infection.

    Methods:

    We report a retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on SARS-CoV-2 infections and vaccination history. We compared reinfection incidence by post-infection vaccination status in individuals initially infected during the April–May 2022 Omicron variant surge in Shanghai and who had been vaccinated before that period. Cox models were fit to estimate adjusted hazard ratios (aHRs).

    Results:

    275,896 individuals were diagnosed with real-time polymerase chain reaction-confirmed SARS-CoV-2 infection in April–May 2022; 199,312/275,896 were included in analyses on the effect of a post-infection vaccine dose. Post-infection vaccination provided protection against reinfection (aHR 0.82; 95% confidence interval 0.79–0.85). For patients who had received one, two, or three vaccine doses before their first infection, hazard ratios for the post-infection vaccination effect were 0.84 (0.76–0.93), 0.87 (0.83–0.90), and 0.96 (0.74–1.23), respectively. Post-infection vaccination within 30 and 90 days before the second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44–0.58) and 0.67 (0.61–0.74), respectively. Moreover, for all vaccine types, but to different extents, a post-infection dose given to individuals who were fully vaccinated before first infection was protective.

    Conclusions:

    In previously vaccinated and infected individuals, an additional vaccine dose provided protection against Omicron variant reinfection. These observations will inform future policy decisions on COVID-19 vaccination in China and other countries.

    Funding:

    This study was funded the Key Discipline Program of Pudong New Area Health System (PWZxk2022-25), the Development and Application of Intelligent Epidemic Surveillance and AI Analysis System (21002411400), the Shanghai Public Health System Construction (GWVI-11.2-XD08), the Shanghai Health Commission Key Disciplines (GWVI-11.1-02), the Shanghai Health Commission Clinical Research Program (20214Y0020), the Shanghai Natural Science Foundation (22ZR1414600), and the Shanghai Young Health Talents Program (2022YQ076).

    1. Epidemiology and Global Health
    Marina Padilha, Victor Nahuel Keller ... Gilberto Kac
    Research Article Updated

    Background:

    The role of circulating metabolites on child development is understudied. We investigated associations between children’s serum metabolome and early childhood development (ECD).

    Methods:

    Untargeted metabolomics was performed on serum samples of 5004 children aged 6–59 months, a subset of participants from the Brazilian National Survey on Child Nutrition (ENANI-2019). ECD was assessed using the Survey of Well-being of Young Children’s milestones questionnaire. The graded response model was used to estimate developmental age. Developmental quotient (DQ) was calculated as the developmental age divided by chronological age. Partial least square regression selected metabolites with a variable importance projection ≥1. The interaction between significant metabolites and the child’s age was tested.

    Results:

    Twenty-eight top-ranked metabolites were included in linear regression models adjusted for the child’s nutritional status, diet quality, and infant age. Cresol sulfate (β=–0.07; adjusted-p <0.001), hippuric acid (β=–0.06; adjusted-p <0.001), phenylacetylglutamine (β=–0.06; adjusted-p <0.001), and trimethylamine-N-oxide (β=–0.05; adjusted-p=0.002) showed inverse associations with DQ. We observed opposite directions in the association of DQ for creatinine (for children aged –1 SD: β=–0.05; pP=0.01;+1 SD: β=0.05; p=0.02) and methylhistidine (–1 SD: β = - 0.04; p=0.04;+1 SD: β=0.04; p=0.03).

    Conclusions:

    Serum biomarkers, including dietary and microbial-derived metabolites involved in the gut-brain axis, may potentially be used to track children at risk for developmental delays.

    Funding:

    Supported by the Brazilian Ministry of Health and the Brazilian National Research Council.